SCHEMBL12037692

SCHEMBL12037692

Cc1ccc2nc(-c3c(Cl)nc(N)nc3N[C@@H]3C[C@H](CO)[C@H]4OC(C)(C)O[C@H]43)oc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 8/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.35
▸ NPC1 O15118 5/20 0.35
▸ RAB9A P51151 5/20 0.35
▸ MAPT P10636 4/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.34
▸ AGPAT2 O15120 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MMP2 P08253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12037696 0.94 IRAK4 (0.49) IRAK4NPC1RAB9AMAPTKDM4E
SCHEMBL12037693 0.86 IRAK4 (0.67) IRAK4
SCHEMBL12037698 0.79 IRAK4 (0.67) IRAK4AGPAT2
SCHEMBL12058200 0.78 IRAK4 (0.43) IRAK4SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL12037685 0.77 IRAK4 (0.57) IRAK4
SCHEMBL12037688 0.75 IRAK4 (0.71) IRAK4
SCHEMBL17119855 0.75 IRAK4 (0.55) IRAK4
SCHEMBL12036743 0.75 IRAK4 (0.55) IRAK4
SCHEMBL12036746 0.75 IRAK4 (0.38) IRAK4
SCHEMBL12037701 0.74 IRAK4 (0.53) IRAK4SMN1; SMN2NPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2011-12-29 — — US disclosed
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2011-12-29 — — US disclosed
WO-2010022121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO IRAK4 706/4885SMN1; SMN2 2306/4885NPC1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback